Xellia Pharmaceuticals Names Baker as Chief Commercial Officer of Xellia North America
16 September 2019 - - Denmark-based specialty anti-infective treatments manufacturer Xellia Pharmaceuticals has appointed Peter Baker as chief commercial officer for Xellia North America, the company said.

Baker was until now the national accounts lead for Xellia North America, building key customer relationships, including Xellia's product supply agreement with Civica Rx announced in May 2019.

He has extensive experience in leading commercial organizations across branded and generic products, achieved over a 30 year career at companies such as Abbott Laboratories, Hospira and Pfizer Inc.

The US sales team was established 12 months ago to enable Xellia's entrance into the US hospital market. Since then Xellia has secured leading market positions for its anti-infective portfolio and developed a pathway for its innovative pipeline.

Baker's role will be to expand upon the US sales success to enable the launch of further dosage forms of Xellia's branded innovative liquid franchise.

The initial product in the liquid franchise was premixed Vancomycin Injection in a Ready-to-Use bag which was approved by the US FDA in February this year for 1 g and 1.5 g presentations.

Following demand from healthcare professionals, Xellia has now launched a 2 g dose of the premixed Vancomycin Injection Ready-to-Use bag the first of its kind. Further additional unique strengths are due for launch in the coming months.

Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercialising anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 100 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable drug products.

Continuing the company's evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R and D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States.

Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,600 people.